KB004: Preliminary Phase I data

Preliminary data from 44 patients with relapsed or refractory hematologic malignancies in an open-label, dose-escalation, U.S. Phase I trial showed that IV KB004 on days 1, 8 and 15 of a 21-day cycle ...